Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial. (2026). SKIN The Journal of Cutaneous Medicine, 10(2), s744. https://doi.org/10.25251/ppt8ep84